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Highlights 
 Mutations in C3 have been associated with aHUS and other glomerulopathies. 
 aHUS-associated C3 mutants R592W, R161W, and I1157T impair regulation by 
MCP, but not by FH,  
 EM analysis provides the structural basis for the functional impairment of the 
R161W and I1157T mutants.  
 Data supports aHUS-associated C3 mutations selectively affect complement 
regulation on surfaces  
 
Abstract 
Atypical hemolytic uremic syndrome (aHUS) associates with complement 
dysregulation caused by mutations and polymorphisms in complement activators and 
regulators. However, the reasons why some mutations in complement proteins 
predispose to aHUS are poorly understood.  Here, we have investigated the functional 
consequences of three aHUS-associated mutations in C3, R592W, R161W and 
I1157T. First, we provide evidence that penetrance and disease severity for these 
mutations is modulated by inheritance of documented “risk” haplotypes as has been 
observed with mutations in other complement genes. Next, we show that all three 
mutations markedly reduce the efficiency of factor I-mediated C3b cleavage when 
catalysed by membrane cofactor protein (MCP), but not when catalysed by factor H. 
Biacore analysis showed that each mutant C3b bound sMCP (recombinant soluble 
MCP; CD46) at reduced affinity, providing a molecular basis for its reduced cofactor 
activity. Lastly, we show by electron microscopy structural analysis a displacement of 
the TED domain from the MG ring in C3b in two of the C3 mutants that explains these 
defects in regulation. As a whole our data suggest that aHUS-associated mutations in 
C3 selectively affect regulation of complement on surfaces and provide a structural 
framework to predict the functional consequences of the C3 genetic variants found in 
patients. 
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Abbreviations 
AP, alternative pathway; aHUS, atypical hemolytic uremic syndrome; CP, classical 
pathway; CR1, complement receptor 1; DAF, decay accelerating factor; DDD, dense 
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recombinant membrane cofactor protein (MCP, CD46); SCR, short consensus repeat; 
SPR, surface Plasmon resonance, wt, wild-type;  
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1. Introduction 
 
Hemolytic uremic syndrome (HUS) is a severe renal disorder characterized by 
Coomb’s negative microangiopathic hemolytic anemia, thrombocytopenia and acute 
renal failure. Typical HUS usually follows a diarrheal episode associated with infection 
by Shiga toxin producing 0157:h7 Escherichia coli. Between 5 and 10% of HUS cases 
are not associated with infection; these have a poor prognosis with multiple 
recurrences and often progress to acute renal failure, with a 30% mortality rate, 
reduced significantly since the introduction of anti-complement therapeutic Eculizumab. 
The majority of cases of this atypical form of HUS (aHUS) are associated with 
mutations or polymorphisms in complement proteins. Renal injury in aHUS is caused 
by complement-mediated endothelial damage with formation of microthrombi that 
occlude kidney arterioles. Arteriole occlusion causes one of the hallmarks of HUS, the 
presence of schistocytes, fragments produced as erythrocytes break up when passing 
at high pressure through partially occluded vessels.  
Complement is a major component of innate immunity with crucial roles in 
microbial killing, apoptotic cell clearance, immune complex handling and modulation of 
adaptive immune responses. Complement activation by three independent activation 
pathways, classical (CP), lectin (LP) and alternative (AP), results in formation of meta-
stable protease complexes, C3-convertases (AP, C3bBb; CP/LP, C4b2a), that cleave 
C3 to generate C3b. Convertase-generated C3b forms more AP C3-convertase, 
providing exponential amplification of initial activation. Binding of C3b to the C3-
convertase generates a C5-cleaving enzyme (C5-convertase) that initiates formation of 
the lytic membrane attack complex (MAC). In health, activation of C3 is restricted and 
deposition of C3b and further activation of complement limited to the surface of 
pathogens by multiple regulatory proteins, including factor H (Sansbury, F.H., et al.), 
C4b-binding protein (C4BP), membrane cofactor protein (MCP), decay accelerating 
factor (DAF), complement receptor 1 (CR1) and CD59, that control complement 
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activation and prevent consumption of components by inactivating C3b or C4b (factor I-
cofactor activity), dissociating the C3/C5 convertases (decay accelerating activity), or 
inhibiting MAC formation (Walport, M.J., 2001a, Walport, M.J., 2001b). 
Mutations in genes encoding the regulatory proteins FH (CFH), MCP (MCP) 
and FI (CFI), and the complement activating components factor B (CFB) and C3, are 
associated with aHUS; importantly, aHUS-associated mutations in regulators are loss-
of-function, while mutations in activators are gain-of-function (Richards, A., et al., 2003, 
Richards, A., et al., 2001, Pérez-Caballero, D., et al., 2001, Goicoechea de Jorge, E., 
et al., 2007, Caprioli, J., et al., 2003, Caprioli, J., et al., 2001, Esparza-Gordillo, J., et 
al., 2005, Sartz, L., et al., 2012, Roumenina, L.T., et al., 2012, Noris, M., et al., 2003, 
Sánchez-Corra, P., et al., 2002, Warwicker, P., et al., 1998, Frémeaux-Bacchi, V., et 
al., 2008, Fremeaux-Bacchi, V., et al., 2004). We present here the functional and 
structural characterization of three C3 mutations found in the Spanish aHUS cohort. All 
three mainly impair regulation of the AP convertase on surfaces by MCP (CD46), an 
effect consistent with the pathogenic mechanisms that characterize aHUS, and we 
provide a structural basis for this impairment. Further, we show that concurrence of 
these C3 mutations with aHUS-conferring risk polymorphisms in the CFH and MCP 
genes modulates penetrance and clinical severity of disease in aHUS. 
  
 6 
2. Patients, Materials and Methods. 
 
2.1. Patients. 
Our series of aHUS patients comprises 237 unrelated individuals, including 214 
Spaniards, seven from other European countries, six from the USA, six from South 
America and four from Tunisia. aHUS was diagnosed by the presence of one or more 
episodes of microangiopathic  hemolytic anemia and thrombocytopenia defined on the 
basis of hematocrit (Ht)<30%, hemoglobin <10mg/dl, serum lactate dehydrogenase 
(LDH)>460U/L, undetectable haptoglobin, fragmented erythrocytes in the peripheral 
blood smear, and platelet count <150,000/µl, associated with acute renal failure. 
Patients with Stx-HUS, defined as the presence of Shiga toxin in the stools (by the 
Vero cell assay) and/or of serum antibodies against Shiga toxin (by ELISA) and/or LPS 
(O157, O26, O103, O111 and O145, by ELISA) were excluded. None of the aHUS 
patients had thrombotic thrombocytopenic purpura-like manifestations. 
 
2.2. Clinical data from the families and the sporadic patient carrying C3 
mutations: 
 
2.2.1 Family HUS19. 
There are three affected individuals (HUS19, II-1, HUS19M, I-1 and HUS19T, I-2) in 
this Spanish pedigree, all of them alive. Patient HUS19 is a 12y-old female who first 
presented at the age of 14 months after a respiratory infection. She has had 8 
recurrences thus far. In all these occasions she was treated with peritoneal dialysis, 
plasmapheresis and plasma infusion and recovered renal function. The family history 
revealed that the mother (HUS19M) and a maternal aunt (HUS19T) also suffered an 
episode of aHUS of unknown origin without recurrence. The mother presented with 
aHUS when she was 6 years old and recovered completely her renal function. The 
aunt had developed aHUS of unknown origin when she was 14 months and also 
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recovered her renal function. However, some neurological deficits remained (epilepsy 
secondary to hypertensive crisis) in this patient. 
 
2.2.2. Family HUS107. 
Patient HUS107 is a female who belongs to another Spanish pedigree. Her mother was 
also affected. Patient HUS107 has a healthy daughter and two unaffected brothers; 
one of them also has two healthy daughters. HUS107 presented with aHUS at the age 
of 35 years associated with the intake of oral contraceptives. This episode was 
complicated by neurological disorders and was treated with antibiotics, 
immunosuppressive drugs (vincristine), plasmapheresis and plasma infusions. 
Currently, she has chronic renal insufficiency and is supported on peritoneal dialysis. 
Her mother presented at the age of 23 and also suffered aHUS associated with 
neurological complications. She received a cadaveric kidney graft at the age of 28 and 
died at the age of 31 with no evidence of recurrence in the grafted kidney. 
 
2.2.3. Patient HUS193. 
This patient presented with aHUS without a clear triggering factor. The biopsy showed 
thrombotic microangiopathy and he recovered completely after 8 months with 
haemodialysis. However, 16 years later he developed terminal renal disease. He is 
currently on haemodialysis waiting for a transplant. This patient shows permanent 
hypocomplementemia with low levels of C3 and CH50 but normal levels of C4.  
 
2.3. Mutation screening/ genotyping. 
The patients were screened for mutations and polymorphisms in CFH, MCP, CFI, 
THBD, CFB and C3 genes by automatic DNA sequencing of PCR amplified fragments. 
Genomic DNA was prepared from peripheral blood cells according to standard 
procedures (Miller, S.A., et al., 1988). Each exon of those genes was amplified from 
genomic DNA by using specific primers derived from the 5’ and 3’ intronic sequences 
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as described (Richards, A., et al., 2003, Pérez-Caballero, D., et al., 2001, Fremeaux-
Bacchi, V., et al., 2004, Miller, S.A., et al., 1988, Delvaeye, M., et al., 2009). Automatic 
sequencing was performed in an ABI 3730 sequencer using a dye terminator cycle 
sequencing kit (Applied Biosystems, Foster City, CA). Copy number variations in the 
CFHR1-R3 genes were analyzed by MLPA as described elsewhere (Abarrategui-
Garrido, C., et al., 2009). 
 
2.4. Purification of complement components and activation fragments 
FH and factor B (FB) were purified from plasma of healthy donors by a two-step 
method as described before (Tortajada, A., et al., 2009). Briefly, filtered plasma was 
applied to a 5 ml affinity column to which 10mg of mouse anti-human FHmAb (35H9) or 
anti-human FBmAb (D2) was coupled. Bound protein was eluted and polished by gel 
filtration on a SuperoseTM 6 10/300 column (GE Healthcare, Chalfont St. Giles, UK). 
sMCP (Standing for soluble MCP) is a recombinant variant of MCP (also known as 
CD46) containing the first four SRCs (SCR1-4), lacking the membrane GPI anchor. 
sMCP was a generous gift from our collaborator Prof. Susan Lea, Oxford University. 
sMCP has been previously used to determine binding affinity with immobilised C3b 
(Heurich, M., et al., 2011). All mutant and native C3 were purified from C3102R 
homozygotes as described before (Martínez-Barricarte, R., et al., 2010). Briefly, C3 
was prepared from plasma containing 20mM EDTA and 10mM benzamidine. 
Supernatant of a 10% (w/v) sodium sulphate precipitation was applied to a lysine-
sepharose column. The flow through was collected and applied to a DEAE-Sepharose 
anion exchange column. Protein was fractionated using a NaCl gradient and C3-
containing fractions were identified by ELISA and applied to a Mono S HR 5/5 cation 
exchange column (GE Healthcare). Protein was eluted and C3-containing peak 
fractions were pooled and preserved frozen at -70ºC. C3b was generated by limited 
digestion with trypsin as previously described (Sánchez-Corral, P., et al., 1989). All 
C3b preparations were polished by gel filtration on a SuperoseTM 6 10/300 column 
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(GE Healthcare) before being used to eliminate any detectable contaminants or 
aggregates. The protocols used were identical for patient-derived mutant C3 and wt 
C3; attempts to separate mutant from wt C3 in patient preparations by differential 
elution from ion exchange matrices were unsuccessful.  
 
2.5. Activation of C3 
Purified C3 (500μg/ml), FB (50μg/ml) and FD (4μg/ml) in 20mM sodium phosphate 
buffer pH 7, 100mM NaCl and 2mM MgCl2 were incubated in a water bath at 37ºC. 
Aliquots of 5μl were extracted from the mix at 0, 0.5, 1, 2, 4, 8, 16, 32 and 60 minutes, 
mixed with SDS-PAGE sample buffer (2% SDS, 62.5 mMTris, 10% Glycerol and 0.75% 
Bromophenol Blue) to stop the reaction and loaded into a 10% reducing SDS-PAGE 
gel. The gels were stained using Coomassie brilliant blue R-250 (Biorad) and digitized 
using a GS-800 densitometer (BioRad) and the MultiGauge software package 
(FUJIFILM). 
 
2.6. Factor H and sMCP cofactor activity for FI-mediated proteolysis of C3b 
The cofactor activities of FH and recombinant sMCP were determined in a C3b 
proteolytic assay using purified proteins. In brief, C3b, FH or sMCP and FI were mixed 
in 10mM Hepes pH 7.5, 150mM NaCl, 0.02% Tween 20. Final concentrations in the 
first set were 350 μg/ml (C3b),17.5μg/ml (FI) and 13 μg/ml (sMCP) and in the second 
set they were 76μg/ml (C3b), 3.8 μg/ml (FI). Mixtures were incubated at 37ºC in a 
water bath and aliquots containing 2μg of C3b collected at 0, 1, 5, and 10 minutes. The 
reaction was stopped by dilution in 5 volumes of SDS sample buffer. Samples were 
analyzed in 10% SDS-PAGE under reducing conditions. Gels were stained with 
Coomassie brilliant blue R-250 (BioRad) and proteolysis of C3b determined by 
analyzing the cleavage of the α’-chain normalizing with the beta chain after scanning 
the gels with a GS-800 calibrated densitometer (BioRad) and the MultiGauge software 
package (FUJIFILM). 
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2.7. Surface plasmon resonance 
Binding affinities of the disease-associated C3 mutants with regulators were measured 
by surface plasmon resonance (SRP) using a Biacore T100 instrument (GE 
Healthcare). A Biacore series S-carboxymethylated dextran (CM5) sensor chip (GE 
Healthcare) was prepared by immobilizing 400 RU C3b (Complement Technology) 
using standard amine coupling. The reference surface of the chip was prepared by 
activating and blocking the chip surface. Experiments were performed at 25°C and at 
20 μl/min. Concentration series of proteins were injected as triplicates in 10 mM 
HEPES-buffered saline with 3 mM EDTA and 0.05% (v/v) surfactant p20 (HBSEP; GE 
Healthcare). Factor H (0.07M to 4.18M) was flowed across C3b for 180 s to achieve 
steady-state conditions, followed by 300s dissociation in running buffer. The surface 
was regenerated between analyte injections using 1M NaCl, 0.1M sodium acetate, 
pH4. For MCP affinity analysis, the surface was adjusted to 1500RU C3b by thioester 
deposition, achieved by flowing FB and FD in the presence of Mg2+ to form C3 
convertase followed by mutant C3 (or wt C3) as substrate (Harris, C.L., et al., 2007). 
Varying concentrations of MCP (0.078 M to 5M) were flowed over the C3b surface 
for 90s to achieve steady-state, followed by dissociation using running buffer for 300s. 
Data were processed using the BIAevaluation software (GE Healthcare). Data were 
double-referenced by subtracting RU shifts from the reference cell and a blank (buffer) 
injection; dissociation constants were calculated using steady-state affinity analysis. 
 
MCP-cofactor activity was assessed on the mutant C3b surface and compared directly 
to the wt C3b surface. Mutant and wt C3b were deposited on the chip via the thioester 
adjusted to an equal density of 1500RU. The C3 convertase was formed prior to FI 
cleavage (0s) by flowing FB (2.38 M) and FD (42nM) in the presence of Mg2+ over 
each surface separately; this confirmed identical convertase formation on both C3b 
surfaces. A fixed concentration of MCP (0.1 μM) and FI (57 nM) was then flowed 
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across the C3b-coated surface at 10 μl/min using four sequential injections (for 60s, 
60s, 90s and finally for 120s) cleaving C3b to iC3b, resulting in subsequent lack of 
affinity for FB. C3 convertase formation was measured at time zero and after each 
injection (% of initial convertase at time 0s equals 100%) and plotted against time of 
MCP/FI exposure to the C3b surface for both mutant and wt C3b. GraphPad Prism 
Version 5.01 software was used to analyse linear regression of C3 convertase 
formation (RU) versus log time (s) yielding the slope and the goodness-of-fit (r2) for 
each curve. The software compared the slopes by calculating a P value (two-tailed) 
that determines the differences in slope values for the mutant versus the wt C3b 
surfaces, determining whether the lines are significantly different.  The inter-
experimental variation was determined by comparing the slopes for separate wt C3b 
experiments against each other and did not differ significantly. 
 
2.8. Electron Microscopy and image processing of C3b mutants 
C3b, C3bR592W, C3bR161W and C3bI1157T were adsorbed on carbon-coated grids and 
stained using 2% uranylformate. All observations were performed using a JEOL-1230 
at 100 kV and images of mutant and wt C3b were recorded using a TVIPS F416 CMOS 
camera and a final magnification of 54926. Images of individual molecules for all 
samples (6712, 7964, 7327 and 6539 images for C3b, C3bR592W, C3bR161W and 
C3bI1157T respectively) were extracted automatically and subsequently classified and 
averaged using XMIPP(Sorzano, C.O., et al., 2004). Image processing and averaging 
revealed that most views of the native and mutant C3b molecules could be assigned to 
views of C3b in which the TED domain was clearly either attached or displaced from 
the MG ring. However, there were some images in all C3b samples that could not be 
assigned to a specific conformation since they corresponded to views of the molecule 
where the position of the TED domain in reference to the MG ring could not be 
determined. These images corresponded to approximately 14% of the images in all 
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experiments (1008, 1379, 1047 and 1520 images for C3b, C3bR592W, C3bR161W and 
C3bI1157T respectively), and they were discarded from the analysis.    
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3. Results 
 
3.1. Identification of C3 mutations in aHUS patients 
The Spanish aHUS cohort comprises 237 unrelated individuals, including 214 
Spaniards, seven other European, six USA, six South America, four Tunisia. Three 
patients (HUS19, HUS107, and HUS193; all Caucasians, Spanish origin; 1.3% of the 
cohort) carried miss-sense mutations in heterozygosis in the C3 gene (Figure 1). The 
mutation in HUS19 located in exon 27 (c.3470T>C) causes the amino acid substitution 
I1157T in the TED domain of C3. This mutation is present in the three aHUS-affected 
members in the HUS19 pedigree, all presenting normal C3 levels (Figure 1a; Table 1). 
HUS107 carries a mutation in exon 4 (c.481C>T) which causes the amino acid 
substitution R161W in the MG2 domain of C3 and also associates with normal C3 
levels. The mutation was found in the patient and her asymptomatic 10 year-old 
daughter (Figure 1b). HUS107 likely inherited the mutation from her aHUS-affected 
mother, but no DNA was available to confirm this. HUS193 carries a mutation in exon 
14, c.1774C>T, that causes the amino acid substitution R592W in the C3 MG6 domain 
(Figure 1c); no family data were available. HUS193 shows low levels of plasma C3. 
The R161W, R592W and l1157T mutations have been previously associated with 
aHUS (Roumenina, L.T., et al., 2012, Frémeaux-Bacchi, V., et al., 2008, Schramm, 
E.C., et al., 2015). Two of these gain-of-function C3 mutations, R161W and I1157T, are 
relatively prevalent mutations representing around 50% of the aHUS patients carrying 
C3 mutations in Europe and Japan, respectively (Schramm, E.C., et al., 2015, Noris, 
M., et al., 2010, Matsumoto, T., et al., 2014, Maga, T.K., et al., 2010, Fan, X., et al., 
2013). Importantly, these mutations are always found associated with aHUS. The 
objective of our work was to confirm previous functional characterization using 
recombinant proteins with plasma purified preparations of these prevalent and aHUS-
specific mutant proteins, and to extend their functional characterization with structural 
data. None of the three C3 mutations described in this report were found in controls, 
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including 128 normal Spaniards, or in public databases, including dbSNP, the 1000 
genome database (1092 subjects, www.1000genomes.org) and the NHLBI GO exome 
sequencing projects (6503 subjects, evs.gs.washington.edu/EVS/) (October 2014). All 
three patients were C3S (C3102R) homozygotes.  
 The heterogeneity of the kidney outcome in our patients is consistent with that 
reported for other aHUS patients carrying the same mutations. In fact, from the 12 
patients carrying the I1157T mutations with reported clinical descriptions, four 
developed a severe disease reaching end stage renal disease (ESRD), while 8 had a 
relapsing disease and/or achieved remission. The same was observed for patients 
carrying the R161W mutation; nine out of 14 reached ESRD and the remaining 5 had 
chronic renal disease (Roumenina, L.T., et al., 2012, Noris, M., et al., 2010, 
Matsumoto, T., et al., 2014, Fan, X., et al., 2013, Fremeaux-Bacchi, V., et al., 2013). 
 
 
3.2. aHUS risk polymorphisms in aHUS patients with mutations in C3. 
To investigate whether clinical variability of disease in C3 mutation carriers is 
influenced by other previously reported CFH and MCP aHUS-associated 
polymorphisms, all patients and relatives were genotyped (Figure 1, Table 1). Patient 
HUS19, who presented a more severe clinical phenotype than her affected mother and 
aunt, including earlier onset and multiple recurrences, carried the MCPGGAAC risk 
haplotype in homozygosis, whereas her relatives carried a single copy of this haplotype 
and one copy of the aHUS-protective CFHGATAAG haplotype (Figure 1a). Patient 
HUS107 carried the MCPGGAAC risk haplotype in heterozygosis and the CFHTGTGGT risk 
haplotype in homozygosis. Her daughter (individual III-3 in pedigree HUS107; Figure 
1b), currently healthy, carried the same C3 mutation with both the protective CFHGATAAG 
haplotype and the CFHTGTGGT risk haplotype in heterozygosis. No family members were 
available for patient HUS193 who had a slowly developing disease and carried both the 
MCPGGAAC risk haplotype and the CFHCATAAG protective haplotype in heterozygosis 
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(Figure 1c). 
 
3.3. Purification of C3 mutant proteins. 
C3 proteins were purified from plasma of appropriate mutant carriers; these 
individuals were heterozygotes and therefore C3 preparations were a mix of mutant 
and wild-type (wt) C3. Proteomic analysis of C3 proteins purified from patients 
confirmed the presence of mutant C3 (Supplementary Table 1); SDS-PAGE under 
reducing conditions separated the C3b -chains corresponding to wt and mutant alleles 
in C3 from patients carrying the R592W and R161W mutations enabling us to estimate 
that mutant C3 protein represented approximately 50% of total circulating C3 in these 
patients (Supplementary Figure 1). By using a mixture of wt and mutant protein 
preparation for our analyses, rather than making homogenous recombinant proteins, 
we provide a clearer picture of the in vivo functional effect as it presents in the patients.  
 
3.4. aHUS-associated C3 mutants are activated normally by the AP C3 
convertase 
The three C3 mutant proteins were incubated with FB and FD at 37ºC and 
cleavage to C3b analysed by SDS-PAGE. For comparison, wt C3 purified from pooled 
normal plasma at same time and using the same method was included. Coomassie-
stained gels and densitometry analyses are shown in Figure 2. All three aHUS-
associated C3 mutants were activated to C3b by the AP C3 convertase normally and at 
similar rates to wt C3. 
 
3.5. Cofactor analysis of aHUS-associated C3 mutants reveals resistance to 
regulation by MCP but not FH. 
C3 preparations from each of the three individuals, and normal C3, were 
converted to C3b using trypsin(Sánchez-Corral, P., et al., 1989) and used to test 
cofactor activities of FH and MCP for FI-mediated C3b cleavage. Identical amounts of 
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each C3b preparation were incubated with FI and either purified FH or soluble 
recombinant MCP (sMCP). All three aHUS mutant C3b proteins were inactivated by FI 
in the presence of FH at a rate indistinguishable from that of wt C3b (Figure 3b). In 
contrast, all three aHUS mutant C3b preparations were partially inactivated by sMCP 
(Figure 3a). An average of 50% of C3bI1157T and 70% of C3bR592W and C3bR161W was 
cleaved, compared to almost complete cleavage of wt C3 after 10 minutes. 
Considering that approximately 50% of the C3 in preparations from patients carrying 
the R592W and R161W mutations is mutant protein, these assays demonstrate 
significant resistance of the C3bR592W and C3bR161W mutant proteins to inactivation by 
MCP, almost complete in the case of the C3bI1157T mutant. These data suggest that 
defective surface regulation is the primary consequence of these aHUS-associated C3 
mutations. 
 
3.6. C3b mutants bind MCP and FH with lower affinity compared to wt.  
To determine whether mutant C3b binds MCP, each C3b preparation was 
immobilized as described in methods and sMCP flowed over the surface. The affinity of 
mutants C3bR592W, C3bR161W and C3bI1157T was reduced compared with wt C3b (Figure 
4a). In complementary experiments testing capacity of MCP to act as a cofactor in the 
FI-mediated inactivation of surface-bound C3b (Figure 5a-f), we found that this 
decreased binding impaired MCP cofactor activity.  MCP-cofactor activity was most 
impaired for C3bI1157T, directly corresponding to the cofactor activity results (Figure 3a). 
The affinity of all mutant C3b preparations for FH was reduced compared with 
wt C3b (Figure 4b) but FH/FI cleavage assays showed no significant difference in FH-
cofactor activity for C3b mutants compared to wt (Figure 3b) in accordance with 
previous reports(Roumenina, L.T., et al., 2012, Frémeaux-Bacchi, V., et al., 2008). 
 
3.7. Structural analysis of the C3b mutants 
 17 
C3b shows characteristic electron microscopy (EM) features that can be directly 
extrapolated to the atomic structure of C3b (Torreira, E., et al., 2009, Nishida, N., et al., 
2006, Janssen, B.J., et al., 2006). The most frequent view, by comparison to crystal 
structures, corresponds to a relatively compact conformation in which the TED domain 
is visualized attached to the MG ring. This conformation represents >90% of EM 
images in native C3b, likely maintained by charge interactions between the domains 
because increasing salt concentration above 50mM NaCl resulted in dramatic 
conformational change with TED domain detachment from the MG ring (not shown). 
We have used these EM analyses to determine whether the overall structure of C3b is 
altered in the C3bR592W, C3bR161W and C3bI1157T mutants. C3bR592W was indistinguishable 
from wt C3b with only a minor proportion of EM images (6% compared to 9% in wt 
C3b) presenting a detached TED domain (Figure 6a). In contrast, EM analysis of 
mutants C3bI1157T and C3bR161W showed 68% and 36% respectively of EM images had 
TED displaced from MG domain. Considering that mutant C3 protein in the C3bI1157T 
and C3bR161W preparations represents approximately 50% of the C3b molecules, these 
data suggest that both I1157T and R161W mutations impact MG/TED domain 
interaction and overall C3b conformation, I1157T mutation having the strongest effect. 
These are important findings because a displaced TED has direct consequences for 
interaction of C3b with the regulators FH(Wu, J., et al., 2009) and MCP(Persson, B.D., 
et al., 2010) (Figures 6b and 7). We recently postulated that TED displacement 
contributes to the increased resistance of properdin-C3bBb complexes(Alcorlo, M., et 
al., 2013) and iC3b(Alcorlo, M., et al., 2011) to accelerated decay or inactivation by 
complement regulators.  
The I1157T and R161W mutations localize to the TED and MG2 domains facing 
the MG1 and CUB domains respectively, and thus it is conceivable that these C3 
mutations could affect, directly or indirectly, stability of contacts between the CUB-TED 
region and the MG ring. TED domain displacement in the C3bI1157T and C3bR161W 
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mutants supports reduced stability of the contacts, which in turn provides a plausible 
explanation for their increased resistance to inactivation by MCP. 
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4. Discussion 
 
aHUS is a rare, life-threatening renal pathology associated with complement 
dysregulation and endothelial cell injury, culminating in formation of microthrombi that 
occlude small vessels in kidney leading to severe renal impairment(Noris, M., et al., 
2009). aHUS has a strong genetic component (Pickering, M.C., et al., 2007, Rodríguez 
de Córdoba, S., et al., 2014) and is strongly associated with polymorphisms and 
mutations in activators (C3 and FB) and regulators (MCP, FI and FH) of the 
complement AP. We identified six carriers of C3 mutations (Figure 1). All were 
heterozygotes and all, excepting a 10 year-old child in pedigree HUS107, have 
developed aHUS. None of these patients carried additional mutations in CFH, MCP, 
CFI or CFB, or CFH-CFHR1/5 rearrangements. Disease severity varied considerably 
among the patients (Supplementary Materials and Methods). To investigate whether 
this clinical variability was influenced by other aHUS genetic risk factors, patients and 
family members were genotyped for CFH and MCP aHUS-associated polymorphisms 
(Caprioli, J., et al., 2003, Esparza-Gordillo, J., et al., 2005, Sánchez-Corral, P., et al., 
1989). Disease severity correlated with the presence of risk haplotypes in CFH and 
MCP in patients HUS19 and HUS107. Although the number of patients reported here is 
too small to draw definitive conclusions, the data suggest that the aHUS phenotype 
associated with the C3 mutations is modulated by common polymorphisms conferring 
risk or protection from aHUS, as demonstrated before for mutations in other 
complement genes (Esparza-Gordillo, J., et al., 2005, Abarrategui-Garrido, C., et al., 
2009, Esparza-Gordillo, J., et al., 2006, Martinez-Barricarte, R., et al., 2008). This 
observation is consistent with the recent demonstration that severity and penetrance of 
aHUS in C3 mutation carriers in the French cohort was influenced by presence of the 
MCP risk haplotype (Roumenina, L.T., et al., 2012), and that risk and protective CFH 
haplotypes impacted on risk in two large aHUS pedigrees(Sansbury, F.H., et al., 2014). 
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MCP and FH are vital cofactors for FI-mediated inactivation of C3b by cleavage 
of the CUB domain. Previous studies of mutations in FH, MCP and C3 suggested that 
aHUS is caused by surface dysregulation of complement, while fluid phase regulatory 
capacity remains normal (Rodríguez de Córdoba et al., 2014). Data presented in this 
report support these suggestions. We illustrate here that despite our C3b mutants have 
reduced affinity for both FH and MCP, they show impaired regulatory function only for 
MCP. This is consistent with previous reports, testing several C3 mutations expressed 
as recombinant proteins, in which it was observed a decreased affinity for MCP and/or 
FH by the majority of the mutant C3b protein tested. Importantly, the R161W mutant 
was included in those studies and when FI-cofactor activity by FH and MCP was tested 
in this mutant it was found that only the regulation by MCP was impaired (Roumenina, 
L.T., et al., 2012, Frémeaux-Bacchi, V., et al., 2008, Schramm, E.C., et al., 2015, 
Maga, T.K., et al., 2010).  
Alignment of MCP1-4 and FH1-4 structures onto C3b highlights important 
differences between these regulators regarding their interaction interfaces on C3b 
(Figure 7a). SCR3 and SCR4 in both FH and MCP interact with overlapping areas of 
C3b spanning a region including MG2/CUB and MG1/TED domains; however, MCP 
SCR3-4 appears significantly more bent (Persson, B.D., et al., 2010). Notably this 
region of C3b is the location of our aHUS-associated C3 mutations and the four C3 
mutations previously described (Roumenina, L.T., et al., 2012, Frémeaux-Bacchi, V., et 
al., 2008), all with differential impact on FH and MCP (Figure 7a).  Unlike their 
homologues in FH, SCR1 and SCR2 in the MCP hockey stick shape are not in contact 
with C3b(Wu, J., et al., 2009, Persson, B.D., et al., 2010, Gordon, D.L., et al., 1995). 
Consistent with these interactions, MCP SCR4 is particularly important for cofactor 
function(Persson, B.D., et al., 2010), whereas FH cofactor activity is largely lost without 
SCR1, implying that the interaction of SCR1 and SCR2 with C3b is crucial for FH 
regulatory activities (Gordon, D.L., et al., 1995). Overall, these data show that the 
location of a mutation in C3 dictates its impact on FH and MCP interaction with C3b 
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and therefore on fluid phase or surface regulation. This provides an explanation for the 
distinction between the three aHUS-associated C3 mutations described here (R592W, 
R161W and I1157T) and the only functionally-characterized dense deposit disease-
associated C3 mutant (C3del923DG)(Martínez-Barricarte, R., et al., 2010); they 
specifically impact the interactions between C3b and MCP or C3b and FH, respectively 
(Figure 7). 
A major novel finding from EM is that two of the mutations (R161W and I1157T) 
disrupt the overall structure of C3b by dislocating the TED domain from the MG ring, 
resulting in increased TED flexibility (Figure 6). A structural model (Figure 7b) 
illustrates that these mutations are close enough to contact regions between MG2/CUB 
and MG1/TED domains, respectively, to impair inter-domain interactions. This 
observation reinforces the concept that TED position is an important modulator of C3b 
interactions with complement regulators, as previously proposed for properdin-C3bBb 
complexes(Alcorlo, M., et al., 2013) and iC3b(Alcorlo, M., et al., 2011) to explain 
resistance to accelerated decay and inactivation by complement regulators.  TED 
domain flexibility and dislocation away from the MG1–MG8 domain core has been 
shown for hydrolysed C3 (C3H2O)(Li, K., et al., 2010), perhaps explaining differences 
between C3b and C3H2O in their interactions with complement regulators; for 
example, the affinity of FH for C3H2O is several fold weaker than the C3b-FH 
interaction(Heurich, M., et al., 2011). 
A recent report used analytical centrifugation, X-ray and neutron scattering to 
show TED domain detachment from MG1 domain when NaCl concentration was 
raised; a salt-bridge between residues E1031 in TED and R102 in MG1 domain was 
implicated in the interaction(Rodriguez, E., et al., 2014). Our data are consistent with 
these results, EM images revealing conformational heterogeneity in positioning of the 
TED domain with respect to the MG ring and demonstrating that mutations around 
TED/MG contact regions dislocate the interaction resulting in increased TED flexibility 
and altered C3b conformation. The R592W mutation located in C3b MG6 does not 
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disrupt TED location (Figure 7); its functional impact thus involves a different 
mechanism, perhaps directly disrupting the C3b interaction surface thereby reducing 
FH and MCP affinity and MCP regulatory capacity.  
In conclusion, we report functional, biochemical and structural explanations of 
the mechanism of pathogenicity of three aHUS-associated C3 mutations; all three 
mainly impair the regulatory action of MCP. These data further support the contention 
that aHUS is caused by surface-restricted AP dysregulation and illustrate the power of 
combining genetic, functional and structural studies of pathogenic mutations to explain 
mechanisms of disease. 
 23 
Disclosures 
Authors declare no financial conflicts of interest. SRdeC has received honoraria 
from Alexion Pharmaceuticals for giving lectures and participating in advisory boards. 
None of these activities has had any influence on the results or interpretation in this 
article. BPM is a Consultant for Glaxo Smith Kline but receives no personal 
remuneration for this work. CLH has a contract of employment with GlaxoSmithKline; 
all work carried out in her lab on this project was completed prior to that employment. 
 
Acknowledgements 
We are grateful to all patients and the collaborating clinicians for their 
participation in this study. We thank the members of Secugen S.L. and the DNA 
sequencing laboratory at the CIB for invaluable technical assistance with patient 
sequencing and genotyping and Dr. Tamara Montes for help at the initial stages of this 
work. The authors are also indebted to Prof. Susan Lea of Oxford University, UK for 
providing recombinant sMCP. Work in this report has been funded by the Spanish 
“Ministerio de Economía y Competitividad” (SAF2011-26583 to SRdeC, PI12-00597 to 
PS-C and SAF2011-22988 to OL), the Fundación Renal Iñigo Alvarez de Toledo, the 
Seventh Framework Programme European Union Project EURenOmics (305608) to 
SRdeC, by a grant from the Autonomous Region of Madrid (S2010/BMD-2316) to 
SRdeC and OL and the Medical Research Council, United Kingdom (G0701298) to 
CLH and BPM. 
 
 24 
References 
1. Sansbury, F. H., Cordell, H., Bingham, C., Bromilow, G., Nicholls, A., Powell, R., 
Shields, B., Smyth, L., Warwicker, P., Strain, L., Wilson, V., Goodship, J. A., Goodship, 
T. H. J. and Turnpenny, P. D. 2014. Factors determining penetrance in familial atypical 
haemolytic uraemic syndrome. J Med Genet. 756-764. 
2. Walport, M. J. 2001a. Complement. N Engl J Med. 1058-1066. 
3. Walport, M. J. 2001b. Complement. N Engl J Med. 1140-1144. 
4. Richards, A., Kemp, E. J., Liszewski, M. K., Goodship, J. A., Lampe, A. K., Decorte, 
R., Müslümanogğlu, M. H., Kavukcu, S., Filler, G., Pirson, Y., Wen, L. S., Atkinson, J. 
P. and Goodship, T. H. 2003. Mutations in human complement regulator, membrane 
cofactor protein (CD46), predispose to development of familial hemolytic uremic 
syndrome. Proc Natl Acad Sci U S A. 12966-12971. 
5. Richards, A., Buddles, M. R., Donne, R. L., Kaplan, B. S., Kirk, E., Venning, M. C., 
Tielemans, C. L., Goodship, J. A. and Goodship, T. H. 2001. Factor H mutations in 
hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell 
recognition. Am J Hum Genet. 485-490. 
6. Pérez-Caballero, D., González-Rubio, C., Gallardo, M. E., Vera, M., López-
Trascasa, M., Rodríguez de Córdoba, S. and Sánchez-Corral, P. 2001. Clustering of 
missense mutations in the C-terminal region of factor H in atypical hemolytic uremic 
syndrome. Am J Hum Genet. 478-484. 
7. Goicoechea de Jorge, E., Harris, C. L., Esparza-Gordillo, J., Carreras, L., Arranz, E. 
A., Garrido, C. A., López-Trascasa, M., Sánchez-Corral, P., Morgan, B. P. and 
Rodríguez de Córdoba, S. 2007. Gain-of-function mutations in complement factor B are 
associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A. 240-
245. 
8. Caprioli, J., Castelletti, F., Bucchioni, S., Bettinaglio, P., Bresin, E., Pianetti, G., 
Gamba, S., Brioschi, S., Daina, E., Remuzzi, G., Noris, M. and HUS/TTP, f. t. I. R. o. R. 
F. 2003. Complement factor H mutations and gene polymorphisms in haemolytic 
 25 
uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are 
strongly associated with the disease. Hum Mol Genet. 3385-3395. 
9. Caprioli, J., Bettinaglio, P., Zipfel, P. F., Amadei, B., Daina, E., Gamba, S., Skerka, 
C., Marziliano, N., Remuzzi, G., Noris, M. and HUS/TTP, t. I. R. o. F. R. 2001. The 
Molecular Basis of Familial Hemolytic Uremic Syndrome: Mutation Analysis of Factor H 
Gene Reveals a Hot Spot in Short Consensus Repeat 20. J Am Soc Nephrol 297-307. 
10. Esparza-Gordillo, J., Goicoechea de Jorge, E., Buil, A., Berges, L. C., López-
Trascasa, M., Sánchez-Corral, P. and Rodriguez de Córdoba, S. 2005. Predisposition 
to atypical hemolytic uremic syndrome involves the concurrence of different 
susceptibility alleles in the regulators of complement activation gene cluster in 1q32. 
Hum Mol Genet. 703-712. 
11. Sartz, L., Olin, A. I., Kristoffersson, A.-C., Ståhl, A.-l., Johansson, M. E., Westman, 
K., Fremeaux-Bacchi, V., Nilsson-Ekdahl, K. and Karpman, D. 2012. A Novel C3 
Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical 
Hemolytic Uremic Syndrome. J Immunol. 2030-2037. 
12. Roumenina, L. T., Frimat, M., Miller, E. C., Provot, F., Dragon-Durey, M.-A., 
Bordereau, P., Bigot, S., Hue, C., Satchell, S. C., Mathieson, P. W., Mousson, C., Noel, 
C., Sautes-Fridman, C., Halbwachs-Mecarelli, L., Atkinson, J. P., Lionet, A. and 
Fremeaux-Bacchi, V. 2012. A prevalent C3 mutation in aHUS patients causes a direct 
C3 convertase gain of function. Blood. 4182-4191. 
13. Noris, M., Brioschi, S., Caprioli, J., Todeschini, M., Bresin, E., Porrati, F., Gamba, 
S., Remuzzi, G. and HUS/TTP, I. R. o. R. a. F. 2003. Familial haemolytic uraemic 
syndrome and an MCP mutation. Lancet. 1542-1547. 
14. Sánchez-Corra, P., Pérez-Caballero, D., Huarte, O., Simckes, A. M., Goicoechea, 
E., López-Trascasa, M. and Rodriguez de Córdoba, S. 2002. Structural and functional 
characterization of factor H mutations associated with atypical hemolytic uremic 
syndrome. Am J Hum Genet. 1285-1295. 
 26 
15. Warwicker, P., Goodship, T. H., Donne, R. L., Pirson, Y., Nicholls, A., Ward, R. M., 
Turnpenny, P. and Goodship, J. A. 1998. Genetic studies into inherited and sporadic 
hemolytic uremic syndrome. Kidney Int. 836-844. 
16. Frémeaux-Bacchi, V., Miller, E. C., Liszewski, M. K., Strain, L., Blouin, J., Brown, A. 
L., Moghal, N., Kaplan, B. S., Weiss, R. A., Lhotta, K., Kapur, G., Mattoo, T., Nivet, H., 
Wong, W., Gie, S., de Ligny, B. H., Fischbach, M., Gupta, R., Hauhart, R., Meunier, V., 
Loirat, C., Dragon-Durey, M.-A., Fridman, W. H., Janssen, B. J. C., Goodship, T. H. J. 
and Atkinson, J. P. 2008. Mutations in complement C3 predispose to development of 
atypical hemolytic uremic syndrome. Blood. 4948-4952. 
17. Fremeaux-Bacchi, V., Dragon-Durey, M.-A., Blouin, J., Vigneau, C., Kuypers, D., 
Boudailliez, B., Loirat, C., Rondeau, E. and Fridman, W. H. 2004. Complement factor I: 
a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet. e84. 
18. Miller, S. A., Dykes, D. D. and Polesky, H. F. 1988. A simple salting out procedure 
for extracting DNA from human nucleated cells. Nucleic Acids Res. 1215. 
19. Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-
Favero, J., Plaisance, S., Claes, B., Lambrechts, D., Zoja, C., Remuzzi, G. and 
Conway, E. M. 2009. Thrombomodulin Mutations in Atypical Hemolytic–Uremic 
Syndrome. N Engl J Med. 345-357. 
20. Abarrategui-Garrido, C., Martínez-Barricarte, R., López-Trascasa, M., Rodríguez 
de Córdoba, S. and Sánchez-Corral, P. 2009. Characterization of complement factor 
H–related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 
associated with atypical hemolytic uremic syndrome. Blood. 4261-4271. 
21. Tortajada, A., Montes, T., Mart  nez-Barricarte, R., Morgan, B. P., Harris, C. L. and 
Rodriguez de Córdoba, S. 2009. The disease-protective complement factor H allotypic 
variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. 
Hum Mol Genet. 3452-3461. 
22. Heurich, M., Martínez-Barricarte, R., Francis, N. J., Roberts, D. L., Rodríguez de 
Córdoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, 
 27 
factor B, and factor H collaborate to determine systemic complement activity and 
disease risk. Proc Natl Acad Sci U S A. 8761-8766. 
23. Martínez-Barricarte, R., Heurich, M., Valdes-Cañedo, F., Vazquez-Martul, E., 
Torreira, E., Montes, T., Tortajada, A., Pinto, S., Lopez-Trascasa, M., Morgan, B. P., 
Llorca, O., Harris, C. L. and Rodríguez de Córdoba, S. 2010. Human C3 mutation 
reveals a mechanism of dense deposit disease pathogenesis and provides insights into 
complement activation and regulation. J Clin Invest. 3702-3712. 
24. Sánchez-Corral, P., Antón, L. C., Alcolea, J. M., Marqués, G., Sánchez, A. and 
Vivanco, F. 1989. Separation of active and inactive forms of the third component of 
human complement, C3, by fast protein liquid chromatography (FPLC). J Immunol 
Methods. 105-113. 
25. Harris, C. L., Pettigrew, D. M., Lea, S. M. and Morgan, B. P. 2007. Decay-
Accelerating Factor Must Bind Both Components of the Complement Alternative 
Pathway C3 Convertase to Mediate Efficient Decay. J Immunol. 352-359. 
26. Sorzano, C. O., Marabini, R., Velázquez-Muriel, J., Bilbao-Castro, J. R., Scheres, 
S. H., Carazo, J. M. and Pascual-Montano, A. 2004. XMIPP: a new generation of an 
open-source image processing package for electron microscopy. J Struct Biol. 194-
204. 
27. Schramm, E. C., Roumenina, L., Rybkine, T., Chauvet, S., Vieira-Martins, P., Hue, 
C., Maga, T., Valoti, E., Wilson, V., Jokiranta, S., Smith, R. J., Noris, M., Goodship, T., 
Atkinson, J. P. and Fremeaux-Bacchi, V. 2015. Functional mapping of the interactions 
between complement C3 and regulatory proteins using atypical hemolytic uremic 
syndrome-associated mutations. Blood. blood-2014-2010-609073. 
28. Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., 
Fenili, C., Castelletti, F., Sorosina, A., Piras, R., Donadelli, R., Maranta, R., van der 
Meer, I., Conway, E. M., Zipfel, P. F., Goodship, T. H. and Remuzzi, G. 2010. Relative 
Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their 
Impact on Clinical Phenotype. Clin J Am Soc Nephrol. 1844-1859. 
 28 
29. Matsumoto, T., Fan, X., Ishikawa, E., Ito, M., Amano, K., Toyoda, H., Komada, Y., 
Ohishi, K., Katayama, N., Yoshida, Y., Matsumoto, M., Fujimura, Y., Ikejiri, M., Wada, 
H. and Miyata, T. 2014. Analysis of patients with atypical hemolytic uremic syndrome 
treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J 
Hematol. 437-442. 
30. Maga, T. K., Nishimura, C. J., Weaver, A. E., Frees, K. L. and Smith, R. J. H. 2010. 
Mutations in alternative pathway complement proteins in American patients with 
atypical hemolytic uremic syndrome. Hum Mutat. E1445-E1460. 
31. Fan, X., Yoshida, Y., Honda, S., Matsumoto, M., Sawada, Y., Hattori, M., Hisanaga, 
S., Hiwa, R., Nakamura, F., Tomomori, M., Miyagawa, S., Fujimaru, R., Yamada, H., 
Sawai, T., Ikeda, Y., Iwata, N., Uemura, O., Matsukuma, E., Aizawa, Y., Harada, H., 
Wada, H., Ishikawa, E., Ashida, A., Nangaku, M., Miyata, T. and Fujimura, Y. 2013. 
Analysis of genetic and predisposing factors in Japanese patients with atypical 
hemolytic uremic syndrome. Mol Immunol. 238-246. 
32. Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., 
Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., Burtey, S., Niaudet, P., 
Deschênes, G., Lebranchu, Y., Zuber, J. and Loirat, C. 2013. Genetics and Outcome of 
Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children 
and Adults. Clinical Journal of the American Society of Nephrology. 554-562. 
33. Torreira, E., Tortajada, A., Montes, T., Rodriguez de Córdoba, S. and Llorca, O. 
2009. 3D structure of the C3bB complex provides insights into the activation and 
regulation of the complement alternative pathway convertase. Proc Natl Acad Sci U S 
A. 882-887. 
34. Nishida, N., Walz, T. and Springer, T. A. 2006. Structural transitions of complement 
component C3 and its activation products. Proc Natl Acad Sci U S A. 19737-19742. 
35. Janssen, B. J., Christodoulidou, A., McCarthy, A., Lambris, J. D. and Gros, P. 
2006. Structure of C3b reveals conformational changes that underlie complement 
activity. Nature. 213-216. 
 29 
36. Wu, J., Wu, Y. Q., Ricklin, D., Janssen, B. J., Lambris, J. D. and Gros, P. 2009. 
Structure of complement fragment C3b-factor H and implications for host protection by 
complement regulators. Nat Immunol. 728-733. 
37. Persson, B. D., Schmitz, N. B., Santiago, C., Zocher, G., Larvie, M., Scheu, U., 
Casasnovas, J. M. and Stehle, T. 2010. Structure of the extracellular portion of CD46 
provides insights into its interactions with complement proteins and pathogens. PLoS 
Pathog. e1001122. 
38. Alcorlo, M., Tortajada, A., Rodríguez de Córdoba, S. and Llorca, O. 2013. 
Structural basis for the stabilization of the complement alternative pathway C3 
convertase by properdin. Proc Natl Acad Sci U S A. 13504-13509. 
39. Alcorlo, M., Martínez-Barricarte, R., Fernández, F. J., Rodríguez-Gallego, C., 
Round, A., Vega, M. C., Harris, C. L., Rodriguez de Cordoba, S. and Llorca, O. 2011. 
Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. 
Proc Natl Acad Sci U S A. 13236-13240. 
40. Noris, M. and Remuzzi, G. 2009. Atypical Hemolytic–Uremic Syndrome. N Engl J 
Med. 1676-1687. 
41. Pickering, M. C., Goicoechea de Jorge, E., Martinez-Barricarte, R., Recalde, S., 
Garcia-Layana, A., Rose, K. L., Moss, J., Walport, M. J., Cook, H. T., Rodriguez de 
Córdoba, S. and Botto, M. 2007. Spontaneous hemolytic uremic syndrome triggered by 
complement factor H lacking surface recognition domains. J Exp Med. 1249-1256. 
42. Rodríguez de Córdoba, S., Hidalgo, M. S., Pinto, S. and Tortajada, A. 2014. 
Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 422-
430. 
43. Esparza-Gordillo, J., Goicoechea de Jorge, E., Garrido, C. A., Carreras, L., López-
Trascasa, M., Sánchez-Corral, P. and Rodriguez de Córdoba, S. 2006. Insights into 
hemolytic uremic syndrome: segregation of three independent predisposition factors in 
a large, multiple affected pedigree. Mol Immunol. 1769-1775. 
 30 
44. Martinez-Barricarte, R., Pianetti, G., Gautard, R., Misselwitz, J., Strain, L., 
Fremeaux-Bacchi, V., Skerka, C., Zipfel, P. F., Goodship, T., Noris, M., Remuzzi, G., 
Rodriguez de Cordoba, S. and HUS, o. b. o. t. E. W. P. o. t. G. o. 2008. The 
Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic 
Syndrome. J Am Soc Nephrol. 639-646. 
45. Gordon, D. L., Kaufman, R. M., Blackmore, T. K., Kwong, J. and Lublin, D. M. 
1995. Identification of complement regulatory domains in human factor H. J Immunol. 
348-356. 
46. Li, K., Gor, J. and Perkins, S. J. 2010. Self-association and domain rearrangements 
between complement C3 and C3u provide insight into the activation mechanism of C3. 
Biochem J. 63-72. 
47. Rodriguez, E., Nan, R., Li, K., Gor, J. and Perkins, S. J. 2014. A revised 
mechanism for the activation of complement C3 to C3b: a molecular explanation of a 
disease-associated polymorphism. J Biol Chem.  
 
  
 31 
FOOTNOTES FOR THE FIGURES 
 
Figure 1. Mutations in the C3 gene in three Spanish aHUS patients. 
Pedigrees of families a) HUS19 and b) HUS107, as well as patient c) HUS193 are 
described. Individuals are identified by numbers within each generation (in Roman 
numbers). Affected individuals are indicated with solid symbols. The six SNPs that 
comprise the CFH haplotypes are represented in columns. The risk-associated CFH-
H3 haplotype is squared in red. The protective CFH-H2 haplotype is squared in green. 
Each triangle indicates one copy of the MCPGGAAC risk haplotype. Patients are indicated 
by an arrow with the appropriate code. Carriers of the heterozygous C3 mutations are 
indicated with a red dot. For each C3 mutation, the chromatogram corresponding to the 
DNA sequence surrounding the mutated nucleotide in C3 is shown for the appropriate 
aHUS patient and for a control sample. The corresponding amino acid sequences for 
the wild type and the mutated alleles are shown. The amino acid and nucleotide 
numbering is referred to the translation start site (Met +1). 
 
Figure 2. Activation assay of mutant C3. 
C3 was mixed with FB and FD and the cleavage of the C3 alpha chain to alpha’ as well 
as the cleavage of FB into Bb (indicated by arrows) was followed over time (time 0’ 
shows C3 control only), as shown (a) in SDS-PAGE gels for wt C3b (top left) and each 
heterozygous mutant C3bR161W (top right), C3bR592W (bottom left), and C3bI1157T (bottom 
right). It is apparent from the gels (a) and the densitometry analysis (b) illustrating the 
C3 cleavage as % alpha/beta chain ratio, that all mutants and the wild type C3 are 
completely activated to C3b after 10 minutes of reaction, and confirmed by Bb 
generation. The experiment was repeated twice with identical results. 
 
Figure 3. Cofactor activity of sMCP and FH for mutant C3b. 
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a) Recombinant sMCP cofactor activity assay shows that all heterozygous C3b 
mutants are more resistant than wt C3b to inactivation by FI in the presence of sMCP. 
After 10 minutes, only half of the mutant I1157T was cleaved. b) FH cofactor activity 
assay shows that mutant and wt C3b are inactivated by FI in the presence of FH at 
similar rates and to similar degrees.  
 
Figure 4. Affinity assays of MCP and FH for the mutant C3 mutants. 
Binding affinities of C3b mutants with complement regulators MCP and FH were 
measured by surface plasmon resonance (SRP). a) Recombinant sMCP binding 
affinities (KD, µM) with C3bR592W (0.71+/-0.02 µM; P=0.0006, n=3), C3bR161W (0.93+/-
0.06; P<0.0001, n=3), and C3bI1157T (0.94+/-0.06 µM; P<0.0001, n=3); all showing 
weaker affinity compared to wt C3b (KD 0.57+/-0.04 µM, n=6). b) FH binding affinities 
(KD, µM) with C3bR592W (2.45+/-0.05 µM; P<0.0001, n=3), C3bR161W (2.39+/-0.07; 
P<0.0001, n=3), and C3bI1157T (1.42+/-0.02 µM; P<0.0001, n=3); all showing weaker 
affinity compared to wt C3b (KD 0.96+/-0.04 µM, n=9). P-values (two-tailed, unpaired t-
test; depicted as asterisk) refer to the comparison of each mutant KD versus wt KD. c) 
Table summarizing affinity (KD, uM; Mean +/- Standard Deviation) values of 
recombinant sMCP or FH binding to immobilized wt and mt C3b. 
 
Figure 5. MCP cofactor assays for the C3 mutants. 
Sensorgrams show C3 convertase formation before (0s) and after sequential (+ 60s, 
60s, 90s, 120s) inactivation of C3b by sMCP and CFI. At time 0s, formation of both 
mutant and wt C3 convertases are identical. C3 convertase formation (RU, maximum 
indicated by asterisk) remaining after sequential exposure to sMCP/FI relative to initial 
convertase (time zero) is shown for a) C3bR161W, b) C3bR592W, and c) C3bI1157T (solid 
black line) compared to wt C3b (dashed grey line). 
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Linear graph (b, d, f) showing percentage C3 convertase formation vs log total 
exposure time (s) after each interval of C3b surface exposure to sMCP/FI. Linear 
regression analysis gives the slope for each curve, which illustrates the rate of C3b 
inactivation over time. Mutant b) C3bR161W (slope: -51.2+/-2.85, r2 = 0.9939, P = 0.02), 
d) C3bR592W (slope: -54.2+/-1.3, r2 = 0.9988, P = 0.003) and f) C3bI1157T (slope: -43.5+/-
0.5, r2 = 0.9997, P=0.001) is resistant to sMCP/FI-mediated inactivation compared to 
wt C3b (slope: -66.5+/-2.6, r2 = 0.9970). Individual wt C3b slopes were compared and 
showed no significant difference (n=3, P = 0.91). 
 
Figure 6. EM analyses of the overall structure of C3b, C3bR592W, C3bR161W and 
C3bI1157T. 
a) Galleries of three representative average images of wt C3b and heterozygous 
mutant C3bI1157T, C3bR161W and C3bR592W obtained by EM at 50 mMNaCl. The total 
number of molecules analyzed and the percentage of single molecule images assigned 
to each conformation after image processing is indicated, together with the statistic 
significance of their differences. A cartoon model for each of the conformations based 
on the structure of C3b is shown (TED domain highlighted in dark grey color). 
b) Cartoon model of the interaction of the SCRs 1-4 of FH (FH1-4; green color) and 
SCRs 1-4 of MCP (rose color) with C3b (grey color) with the regular structure in the 
upper panel and with the one with the delocalized TED domain on the lower one, 
based on the crystal structure of C3b-FH (Wu, J., et al., 2009)  and the proposed model 
for the interaction between C3b and MCP (See also Figure 7). 
 
Figure 7. Structural implications for the aHUS-associated C3 mutations. 
a) Cartoon diagram (two views) of C3b in complex with the four SCRs of FH (PDB 
2WII) and with MCP (3O8E) aligned at SCR3 with respect to FH. In green are the 
heterozygous mutations in C3 described in this report and those described earlier by 
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Fremeaux-Bacchiet al.(Frémeaux-Bacchi, V., et al., 2008) that have functional 
consequences, in orange is the C3 mutation C3923ΔDG, the only mutation linked to 
dense deposit disease (DDD) that has been functionally characterized thus 
far(Martínez-Barricarte, R., et al., 2010). b) Enlarged image of the C3b region  
including the C3bR592W, C3bR161W and C3bI1157T mutations. 
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Table 1: Complement and genetic data in individuals carrying the C3 mutations 
 
 
 
     Additional aHUS genetic factors 
ID 
C3 levels 
(80-177mg/dL) 
fB levels 
(>17mg/dL) 
C4 levels 
(14-47mg/dL) 
fH levels 
(5-35mg/dL) 
MCPGGAAC CFHTGTGGT CFHGATAAG 
HUS19 110 26.7 21.4 16.08 Yes (Hom) No No 
HUS19 (I-2) 95 25.7 23.9 10.87 Yes (Het) No Yes (Het) 
HUS19 (I-3) 107 25.7 15 19.19 Yes (Het) No Yes (Het) 
HUS107 91.1 33.2 13.2 22.2 Yes (Het) Yes (Hom) No 
H107 (III-3)* 92.5 22.8 16.5 15 No Yes (Het) Yes (Het) 
HUS193 46.6 15.7 39.1 43.84 Yes (Het) No Yes (Het) 
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